QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.104.005272v1 67/3/744    most recent Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krishnan, V. Articles by Bryant, H. U. Search for Related Content PubMed PubMed Citation Articles by Krishnan, V. Articles by Bryant, H. U.

ORIGINAL ARTICLE

The Nongenotropic Synthetic Ligand 4-Estren-317-diol Is a High-Affinity Genotropic Androgen Receptor Agonist

Musculoskeletal Research (V.K., H.A.B., B.C.Y., M.L., K.C., H.U.B.), Lead Optimization Biology & Business Operations (R.J.B., C.M.R.), Discovery Chemistry Research (J.A.D.), Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Abstract

The nongenotropic ligand estren (Science 298:843–846, 2002) was evaluated for its transcriptional activity mediated by the human androgen receptor (AR). Our results show that estren can bind, translocate, transactivate, and regulate two known target genes of AR in androgen-responsive cell lines. Estren binds recombinant AR with 10-fold higher affinity than either estrogen receptor (ER)- or ER. Estren-bound AR can translocate AR to the nucleus and stimulate the androgen response element-luciferase reporter activity with an efficacy similar to that of androgen. Estren also increased the expression of prostate-specific antigen (PSA) in a dose-dependent manner in human LnCaP cells. Using chromatin immunoprecipitation analysis, we show that the estren-bound AR coimmunoprecipitates with a region of the PSA gene promoter. Therefore, cotreatment with an AR antagonist, bicalutamide, blocked the estren-induced increase in PSA expression. In contrast, phosphoinositol 3-kinase inhibitor wortmannin, or extracellular signal-regulated kinase inhibitor 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophynyltio)butadiene (U0126), and ER antagonist ICI-182780 failed to block the effects of estren. In vivo analysis of estren's action on male-orchidectomized ICR mice revealed estren's AR agonist actions on the levator ani and seminal vesicle target tissues. Taken together, our results reveal the hitherto unidentified genotropic action of estren mediated by AR in androgen-responsive cells and tissues.

Address correspondence to: Dr. Venkatesh Krishnan, 355 East Merrill Street, DC 0434, Lilly Research Labs, Indianapolis, IN 46225. E-mail: Krishnan_Gary{at}lilly.com

This article has been cited by other articles:

				S. Kousteni, M. Almeida, L. Han, T. Bellido, R. L. Jilka, and S. C. Manolagas Induction of Osteoblast Differentiation by Selective Activation of Kinase-Mediated Actions of the Estrogen Receptor Mol. Cell. Biol., February 15, 2007; 27(4): 1516 - 1530. [Abstract] [Full Text] [PDF]

				S. C. Hewitt, J. Collins, S. Grissom, K. Hamilton, and K. S. Korach Estren Behaves as a Weak Estrogen Rather than a Nongenomic Selective Activator in the Mouse Uterus Endocrinology, May 1, 2006; 147(5): 2203 - 2214. [Abstract] [Full Text] [PDF]

eLetters: